TY - BOOK AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2016 PB - A cancer journal for clinicians CY - CA ID - Siegel2015 ER - TY - JOUR AU - Eser, S. PY - 2014 DA - 2014// TI - Oncogenic KRAS signalling in pancreatic cancer JO - Br J Cancer VL - 111 UR - https://doi.org/10.1038/bjc.2014.215 DO - 10.1038/bjc.2014.215 ID - Eser2014 ER - TY - JOUR AU - Burris, H. A. PY - 1997 DA - 1997// TI - Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial JO - J Clin Oncol VL - 15 UR - https://doi.org/10.1200/JCO.1997.15.6.2403 DO - 10.1200/JCO.1997.15.6.2403 ID - Burris1997 ER - TY - JOUR AU - Heinemann, V. PY - 2006 DA - 2006// TI - Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.1490 DO - 10.1200/JCO.2005.05.1490 ID - Heinemann2006 ER - TY - JOUR AU - Heinemann, V. AU - Haas, M. AU - Boeck, S. PY - 2012 DA - 2012// TI - Systemic treatment of advanced pancreatic cancer JO - Cancer Treat Rev VL - 38 UR - https://doi.org/10.1016/j.ctrv.2011.12.004 DO - 10.1016/j.ctrv.2011.12.004 ID - Heinemann2012 ER - TY - STD TI - Goldstein, D., et al., nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of the National Cancer Institute, 2015. 107(2): p. dju413. ID - ref6 ER - TY - JOUR AU - Shin, S. H. PY - 2013 DA - 2013// TI - Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival JO - Pancreas VL - 42 UR - https://doi.org/10.1097/MPA.0b013e31825b6ab0 DO - 10.1097/MPA.0b013e31825b6ab0 ID - Shin2013 ER - TY - JOUR AU - Sinn, B. V. PY - 2014 DA - 2014// TI - KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma JO - Pancreas VL - 43 UR - https://doi.org/10.1097/MPA.0000000000000077 DO - 10.1097/MPA.0000000000000077 ID - Sinn2014 ER - TY - JOUR AU - Miglio, U. PY - 2014 DA - 2014// TI - KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance JO - Pathology-Research and Practice VL - 210 UR - https://doi.org/10.1016/j.prp.2014.01.011 DO - 10.1016/j.prp.2014.01.011 ID - Miglio2014 ER - TY - JOUR AU - Lee, J. PY - 2007 DA - 2007// TI - Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22559 DO - 10.1002/cncr.22559 ID - Lee2007 ER - TY - JOUR AU - Boeck, S. PY - 2013 DA - 2013// TI - EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2012.495 DO - 10.1038/bjc.2012.495 ID - Boeck2013 ER - TY - JOUR AU - Kruger, S. PY - 2014 DA - 2014// TI - Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts JO - World J Gastroenterol: WJG VL - 20 UR - https://doi.org/10.3748/wjg.v20.i31.10769 DO - 10.3748/wjg.v20.i31.10769 ID - Kruger2014 ER - TY - JOUR AU - Kim, S. T. PY - 2011 DA - 2011// TI - Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-11-0269 DO - 10.1158/1535-7163.MCT-11-0269 ID - Kim2011 ER - TY - JOUR AU - Boeck, S. PY - 2013 DA - 2013// TI - KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer JO - J Gastroenterol VL - 48 UR - https://doi.org/10.1007/s00535-013-0767-4 DO - 10.1007/s00535-013-0767-4 ID - Boeck2013 ER - TY - STD TI - Allegra, C.J., et al., Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti–epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. Journal of clinical Oncology, 2015: p. JCO 2015.63. 9674. ID - ref15 ER - TY - JOUR AU - Wolff, A. C. PY - 2013 DA - 2013// TI - Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update JO - Arch Pathol Lab Med VL - 138 UR - https://doi.org/10.5858/arpa.2013-0953-SA DO - 10.5858/arpa.2013-0953-SA ID - Wolff2013 ER - TY - JOUR AU - Misale, S. PY - 2012 DA - 2012// TI - Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer JO - Nature VL - 486 ID - Misale2012 ER - TY - JOUR AU - Diaz, L. A. PY - 2012 DA - 2012// TI - The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers JO - Nature VL - 486 ID - Diaz2012 ER - TY - JOUR AU - Gerlinger, M. PY - 2012 DA - 2012// TI - Intratumor heterogeneity and branched evolution revealed by multiregion sequencing JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113205 DO - 10.1056/NEJMoa1113205 ID - Gerlinger2012 ER - TY - JOUR AU - Birkbak, N. J. AU - Hiley, C. T. AU - Swanton, C. PY - 2015 DA - 2015// TI - Evolutionary precision medicine: a role for repeat epidermal growth factor receptor analysis in ALK-rearranged lung adenocarcinoma? JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.63.2976 DO - 10.1200/JCO.2015.63.2976 ID - Birkbak2015 ER - TY - STD TI - Cai, W., et al., Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. Journal of Clinical Oncology, 2015: p. JCO. 2014.58. 8293. ID - ref21 ER - TY - JOUR AU - Embuscado, E. E. PY - 2005 DA - 2005// TI - Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy JO - Cancer biology & therapy VL - 4 UR - https://doi.org/10.4161/cbt.4.5.1663 DO - 10.4161/cbt.4.5.1663 ID - Embuscado2005 ER - TY - JOUR AU - Yachida, S. PY - 2010 DA - 2010// TI - Distant metastasis occurs late during the genetic evolution of pancreatic cancer JO - Nature VL - 467 UR - https://doi.org/10.1038/nature09515 DO - 10.1038/nature09515 ID - Yachida2010 ER - TY - JOUR AU - Ogino, S. PY - 2005 DA - 2005// TI - Sensitive sequencing method for KRAS mutation detecting by pyrosequencing JO - The Journal of Molecular Diagnostics VL - 7 UR - https://doi.org/10.1016/S1525-1578(10)60571-5 DO - 10.1016/S1525-1578(10)60571-5 ID - Ogino2005 ER - TY - JOUR AU - Kinugasa, H. PY - 2015 DA - 2015// TI - Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29364 DO - 10.1002/cncr.29364 ID - Kinugasa2015 ER -